What is Novo Nordisk's latest dividend and current dividend yield?

What does Novo Nordisk do and what are its main business segments?

What guidance did Novo Nordisk's management provide for the next earnings period?

What were the key takeaways from Novo Nordisk's earnings call?

Did Novo Nordisk beat or miss consensus estimates last quarter?

What is the revenue and EPS growth rate for Novo Nordisk year over year?

What factors drove the changes in Novo Nordisk's revenue and profit?

What is Novo Nordisk's gross profit margin?

- **H1 2025 Strong Growth, Lowered FY25 Guidance**: 18% sales growth vs. prior 12-18% range, but下调全年指引至8-14% due to U.S. market softness.
- **Wegovy Leadership**: U.S. prescriptions 280k/week, 125% IO obesity sales growth, but cash channel penetration lagging (10% vs. 20% target).
- **R&D Pipeline Momentum**: Amycretin Phase III启动，CagriSema扩展试验，semaglutide MASH decision expected Q3.
- **Strategic Shift**: 新CEO Doustdar强调execution, efficiency, and innovation, with R&D and commercial restructuring.
- **Key Risks**: U.S. compounding持续影响，中国GLP-1 destocking，FY25 free cash flow down 19% YoY.

**【CEO Summary Section】**
- Delivered 18% sales growth and 29% operating profit growth in H1 2025, but lowered full-year outlook due to slower-than-expected growth in U.S. obesity and diabetes markets, and lower-than-expected Wegovy penetration in select international markets.
- Highlighted purpose-driven growth: now serving 46 million patients globally, up 3.5 million YoY.
- R&D progress: Ozempic received EMA positive opinion for peripheral arterial disease; amycretin Phase III program (AMAZE) to start in Q1 2026; CagriSema Phase IIIb trial (REDEFINE 11) initiated.
- Strategic shift: Mike Doustdar to become CEO, with focus on sharpening commercial execution, operational efficiency, and innovation.

**【CFO Financial Commentary】**
- H1 2025 sales: DKK 101.3 billion (16% YoY growth in kroner, 18% at CER). Operating profit: DKK 30.3 billion (25% YoY growth in kroner, 29% at CER).
- Gross margin: 83.4% (down 1.5ppts YoY due to Catalent amortization and capacity expansion costs).
- Free cash flow: DKK 33.6 billion (down 19% YoY due to higher capex for API and fill/finish capacity).
- Updated FY25 guidance: Sales growth 8-14% (vs. prior 12-18%), operating profit growth 10-16% (vs. prior 14-20%).
- Key risks: U.S. GLP-1 volume growth slower than expected, compounding impact on branded obesity market.

**【Commercial Execution Updates】**
- **U.S. Operations (Dave Moore):**
  - Wegovy sales +37% H1 2025, 280k weekly prescriptions. Cash channel penetration 10% vs. target 20% by end-2025.
  - CVS Formulary impact: Wegovy now only GLP-1 covered for obesity, early data shows positive trend.
  - Compounding issue persists: ~1 million patients on unsafe compounded GLP-1s, NovoCare Pharmacy launched to expand direct-to-patient access.
- **International Operations (Mike Doustdar):**
  - GLP-1 diabetes sales +10%, obesity care sales +125% (Wegovy alone +335%).
  - Wegovy launched in 35 countries, targeting additional markets in H2 2025.
  - China GLP-1 market growth constrained by wholesaler destocking, but gaining share despite generics threat.

**【R&D Pipeline Highlights】**
- **Amycretin (Phase Ib/IIa):** 22-24% weight loss at 20mg/60mg doses, safety profile consistent with GLP-1 class. Phase III AMAZE program to start Q1 2026.
- **CagriSema (Phase IIIb):** REDEFINE 11 trial testing dose escalation and longer duration.
- **Semaglutide 7.2mg:** EMA submission for MASH indication, U.S. decision expected Q3 2025.
- **Coramitug:** Phase II success in ATTR cardiomyopathy, Phase III to start 2025.
- **Semaglutide Alzheimer's trial:** EVOKE Phase III readout expected late 2025 (high risk/reward).

**【Q&A Highlights】**
- **Compounding Litigation:** Novo Nordisk pursuing legal actions to stop unlawful compounding, but acknowledges broader court decision may be needed.
- **China Strategy:** Focus on expanding GLP-1 sales force, targeting Tier 2-4 cities. Confident in long-term growth despite generics threat.
- **Capacity Constraints:** IO Wegovy launches up 4x YoY, oral semaglutide for obesity to launch 2026 with non-supply-constrained capacity.
- **Rybelsus Deprioritization:** Commercial focus shifting to Ozempic and Wegovy, but not signaling flatlining.
- **SURPASS-CVOT Impact:** Semaglutide's 26% CV risk reduction vs. 12% for tirzepatide reinforces leadership in cardiometabolic benefits.


Novo Nordisk A/S (NVO) Q2 2025 Earnings Call Transcript

- **Q1 Growth**: 18% sales growth driven by GLP-1 treatments, despite 37% carbon emissions rise from production expansion. 
- **R&D Breakthroughs**: CagriSema trial success; Wegovy 2.4mg granted FDA priority review for MASH. 
- **U.S. Market Challenges**: Reduced 2025 outlook due to 1M+ patients on compounded GLP-1, but 70%+ expected to shift to branded post-May 22 enforcement. 
- **Strategic Responses**: $499/month direct-to-patient delivery, 9,000 CVS store partnerships, and telehealth collaborations. 
- **Financial Focus**: Gross margin pressure (83.5%) offset by 19% R&D spend growth; 2025 capex DKK65B for API capacity. 
- **Key Risks**: U.S. compounding impact, but 64% IO market share and 50% U.S. GLP-1 leadership provide resilience. 


**【CEO Summary Section】**
- **Q1 2025 Performance**: 18% sales growth (DKK 24.3 billion) and 20% operating profit growth, driven by GLP-1 treatments in diabetes and obesity. 
- **Patient Impact**: Nearly 46 million patients treated, up 4 million YoY. Carbon emissions rose 37% due to production expansion. 
- **R&D Milestones**: Completed pivotal CagriSema trial for obesity; FDA accepted Wegovy 2.4mg for MASH with priority review. 
- **U.S. Market Challenges**: Lower-than-expected branded GLP-1 penetration due to compounding, leading to reduced full-year outlook. 
- **Strategic Initiatives**: Expanded telehealth partnerships (e.g., HIMS), direct-to-patient delivery at $499/month, and CVS formulary placement. 
- **Supply Chain**: $24B invested in U.S. manufacturing over 10 years; Bloomington, NC facility expansions ongoing. 
- **Management Changes**: Restructured executive team to enhance decision-making speed and execution focus. 

**【CFO Financial Commentary】**
- **Q1 Financials**: Gross margin 83.5% (down 1.3pp YoY) due to production costs; R&D expenses up 19% YoY. 
- **Updated Guidance**: 2025 sales growth 13-21% (prev. 15-23%), operating profit 16-24% (prev. 18-26%). 
- **Key Drivers**: U.S. compounding impact (est. 1M+ patients on compounded GLP-1), but 70%+ of compounding expected to shift to branded products post-May 22 FDA enforcement. 
- **Cash Flow**: Free cash flow DKK9.5B (up 90% YoY); capex DKK13.4B for API and fill-finish capacity. 
- **Shareholder Returns**: DKK36.7B returned via dividends; no buyback program in 2025. 

**【Q&A Highlights】**
- **Compounding Strategy**: 70% of compounding semaglutide; 64% market share in IO. NovoCare pharmacy now available in 9,000 CVS stores. 
- **Mounjaro Competition**: Ozempic maintains 50% U.S. GLP-1 market share; IO sales up 13% with improved supply. 
- **Oral Semaglutide**: FDA review expected H2 2025; 33M patient-years of safety data. 
- **Political Risks**: Limited Medicare exposure for Wegovy; IRA negotiations ongoing. 
- **Stay Time**: Average 7.4 months (up from 6.8Q4 2024), reflecting patient satisfaction with weekly dosing. 


Novo Nordisk A/S (NVO) Q1 2025 Earnings Call Transcript

- **26% sales growth**: Driven by GLP-1 diabetes (+22%) and obesity care (+57%).
- **CagriSema breakthrough**: 22.7% weight loss vs. 16.1% for semaglutide, with Phase III trial expansion.
- **2025 outlook**: 16-24% sales growth, 19-27% operating profit growth, DKK 75-85B free cash flow.
- **Pipeline strength**: 7.2mg semaglutide, oral semaglutide 25mg, and amycretin Phase III trials planned.

**【CEO Summary Section】**
- Delivered 26% sales growth in 2024, driven by GLP-1 portfolio expansion and obesity care. Served 45 million patients globally, up 4 million YoY.
- Emphasized sustainability with 42% women in senior leadership and 23% increase in carbon emissions due to production scale-up.
- Highlighted R&D momentum with CagriSema and amycretin trials, targeting 2025 regulatory submissions.

**【Commercial Execution (Camilla Sylvest)】**
- Total sales growth: 26% (2024), with North America +30%, International +19%.
- GLP-1 diabetes sales: +22% (North America +23%, Intl +18%). Insulin: +17% (North America +52%). Obesity care: +57% (Wegovy global +86%).
- Market leadership: 52% U.S. GLP-1 share, 64% Intl GLP-1 share.

**【U.S. Operations (David Moore)】
- Wegovy U.S. prescriptions: 200,000/week (vs. 100,000 in Q1 2024), 55M covered lives with <$25 copay.
- Facing supply constraints but expanding fill/finish network to 14 sites (from 11) via Catalent acquisition.
- Combatting compounding pharmacies with regulatory actions and patient education.

**【R&D Pipeline (Martin Holst Lange)】**
- CagriSema: 22.7% weight loss at 68 weeks vs. 16.1% for semaglutide. REDEFINE 11 trial to test dose escalation.
- Semaglutide 7.2mg: 20.7% weight loss vs. 17.5% for 2.4mg. Oral semaglutide 25mg filing planned for Q1 2025.
- Amycretin: 22% weight loss at 20mg dose in Phase I/II. Phase III planned for obesity and diabetes.

**【Financial Highlights (Karsten Munk Knudsen)】**
- 2024 sales: DKK 179.3B (+25% DKR, +26% CER). Gross margin: 84.7% (vs. 84.6% 2023).
- R&D spend: DKK 30.3B (+48% DKR). Operating profit: DKK 63.3B (+25% DKR).
- 2025 guidance: Sales growth 16-24% CER, operating profit +19-27% CER. Free cash flow: DKK 75-85B.
- Share buyback: DKK 64.3B returned in 2024, no new buyback program in 2025.


NVO

NVO fundamentals

Earnings Call

You can ask Aime